文献速递流行病学与生物统计真实世界研究与卫生经济

重症监护病房患者生命支持使用与结局

Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units.
PubMed 文献 · JAMA · 2025-01-01

该回顾性队列研究基于美国54个卫生系统2014-2023年数据,纳入3,453,687例成人ICU住院患者,描述新冠疫情前、中、后美国重症监护的流行病学特征。结果显示,疫情期间调整后院内死亡率在新冠阴性(aOR 1.3)和阳性(aOR 4.3)患者中均升高,至2022年中期回落至基线;此后机械通气使用率低于疫情前,而血管升压药使用增加。

要点

  • 疫情期间调整后院内死亡率在新冠阴性(aOR 1.3)和阳性(aOR 4.3)患者中均升高,至2022年中期回落至基线。
  • 有创机械通气率疫情前为23.2%,疫情期间升至25.8%,此后降至22.0%,低于疫情前基线。
  • 血管升压药使用从7.2%增至21.6%的ICU住院。

核心结论

  • 疫情期间美国ICU患者住院时长和调整后院内死亡率的增加已回落至近期历史基线。
  • 目前接受机械通气的患者少于疫情前,而接受血管升压药的患者增多。

研究设计与样本

  • 回顾性队列研究,使用2014-2023年持续贡献数据的54个美国卫生系统Epic Cosmos数据库。
  • 纳入因任何原因入住ICU的成人患者,共3,453,687例ICU住院。
  • 暴露包括患者人口学特征、COVID-19状态和疫情时期。

主要发现

  • 患者中位年龄65岁(IQR 53-75),55.3%为男性,17.3%为黑人,6.1%为西班牙裔或拉丁裔,总体院内死亡率为10.9%。
  • 调整后院内死亡率在疫情期间升高:新冠阴性患者aOR 1.3(95%CI 1.2-1.3),新冠阳性患者aOR 4.3(95%CI 3.8-4.8),至2022年中期回落至基线。
  • 中位ICU住院时长为2.1天(IQR 1.1-4.2),疫情期间新冠阳性患者较新冠阴性患者延长2.0天(95%CI 2.0-2.1)。
  • 有创机械通气率疫情前为23.2%(95%CI 23.1%-23.2%),疫情期间升至25.8%(95%CI 25.8%-25.9%),此后降至22.0%(95%CI 21.9%-22.2%),低于疫情前基线。
  • 血管升压药使用从7.2%增至21.6%的ICU住院。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nationwide data are unavailable regarding changes in intensive care unit (ICU) outcomes and use of life support over the past 10 years, limiting understanding of practice changes. OBJECTIVE: To portray the epidemiology of US critical care before, during, and after the COVID-19 pandemic. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of adult patients admitted to an ICU for any reason, using data from the 54 US health systems continuously contributing to the Epic Cosmos database from 2014-2023. EXPOSURES: Patient demographics, COVID-19 status, and pandemic era. MAIN OUTCOMES AND MEASURES: In-hospital mortality unadjusted and adjusted for patient demographics, comorbidities, and illness severity; ICU length of stay; and receipt of life-support interventions, including mechanical ventilation and vasopressor medications. RESULTS: Of 3 453 687 admissions including ICU care, median age was 65 (IQR, 53-75) years. Patients were 55.3% male; 17.3% Black and 6.1% Hispanic or Latino; and overall in-hospital mortality was 10.9%. The adjusted in-hospital mortality was elevated during the pandemic in COVID-negative (adjusted odds ratio [aOR], 1.3 [95% CI, 1.2-1.3]) and COVID-positive (aOR, 4.3 [95% CI, 3.8-4.8]) patients and returned to baseline by mid-2022. The median ICU length of stay was 2.1 (IQR, 1.1-4.2) days, with increases during the pandemic among COVID-positive patients (difference for COVID-positive vs COVID-negative patients, 2.0 days [95% CI, 2.0-2.1]). Rates of invasive mechanical ventilation were 23.2% (95% CI, 23.1%-23.2%) before the pandemic, increased to 25.8% (95% CI, 25.8%-25.9%) during the pandemic, and declined below prepandemic baseline thereafter (22.0% [95% CI, 21.9%-22.2%]). The use of vasopressors increased from 7.2% to 21.6% of ICU stays. CONCLUSIONS AND RELEVANCE: Pandemic-era increases in length of stay and adjusted in-hospital mortality among US ICU patients returned to recent historical baselines. Fewer patients are now receiving mechanical ventilation than prior to the pandemic, while more patients are administered vasopressor medications.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Moin EE, Seewald NJ, Halpern SD, et al. Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units. JAMA. 2025. PMID: 40227733. doi:10.1001/jama.2025.2163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。